The Effect of Decitabine Dose Modification and Myelosuppression on Response and Survival in Patients With Myelodysplastic Syndromes
|
May 2014
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?
|
Sep 2017
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.
|
Jan 2019
|
Leuk Lymphoma.
|
myelodysplastic syndromes (MDS)
|
MicroRNA-194-5p could serve as a diagnostic and prognostic biomarker in myelodysplastic syndromes
|
Apr 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Aplastic Anemia & MDS International Foundation: Bone marrow failure disease scientific symposium 2012
|
May 2013
|
Leuk Res
|
aplastic anemia
|
Prognostic value of telomere attrition in patients with aplastic anemia.
|
May 2013
|
Leuk Res
|
aplastic anemia
|
Relationship between lenalidomide dose modification, duration of therapy, and long-term outcomes in patients with myelodysplastic syndromes
|
Oct 2017
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes
|
Jan 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Impact of tobacco usage on disease outcome in myelodysplastic syndromes
|
Apr 2015
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
Myelodysplastic syndromes should been renamed as myelodysplastic neoplasms.
|
Jan 2013
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|